Q-omics provides the consensus-scored CDKN1A profile across patient tissues and cancer cell-line models. CDKN1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CDKN1A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CDKN1A RNA expression shows 16,751 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, COAD, and TGCT as cancer lineages where CDKN1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDKN1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDKN1A survival associations across molecular data types. CDKN1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDKN1A RNA expression–survival associations across cancer types. High CDKN1A expression shows unfavorable associations in MESO, UVM and LUAD, but favorable associations in UCEC, KIRC and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify UCEC as the clearest survival context for CDKN1A RNA expression.
This table summarizes CDKN1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDKN1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDKN1A shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, THCA, KIRC and KIRP. The COAD box plot shows higher CDKN1A RNA expression in normal versus tumor tissue (log2 FC = −1.276, t-test p < 0.001).
This table shows molecular features associated with CDKN1A in patient tissues and cancer cell lines. In patient samples, CDKN1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDKN1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
